Vertex Pharma (VRTX), Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Go back to Vertex Pharma (VRTX), Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance

April 29, 2020 4:04 PM EDT

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $2.56, $0.72 better than the analyst estimate of $1.84. Revenue for the quarter came in at $1.52 billion versus the consensus estimate of $1.29 billion.

"The COVID-19 pandemic has presented unprecedented challenges to societies, communities and businesses around the world, and while these global challenges will... More